- Published at
- by investing.com
positive
positive
LifeMD CEO Justin Schreiber sells $129,667 in stock By Investing.com
LifeMD CEO Justin Schreiber sells $129,667 in stock
News for Conversion Labs Inc (CVLB)
- Published at
- by seekingalpha.com
positivepositiveLifeMD's Revival: The Phoenix Of The Health Industry (NASDAQ:LFMD)
LifeMD, Inc.'s soaring share price reflects its commitment to full patient care through GLP-1 meds integration and primary care services. Click here for more on LFMD.- Published at
- by seekingalpha.com
mixedmixedLifeMD Stock: Behind The Lazarus-Like Move (NASDAQ:LFMD)
LifeMD shares have cratered 85% from their all-time high of February 2021, as profitability had been elusive. Click here for more on LFMD.- Published at
- by seekingalpha.com
positivepositiveLifeMD Q3 Earnings: Taking The Business Towards Profitability (NASDAQ:LFMD)
LifeMD is taking steps to be profitable by 2023, such as cutting costs and getting more customers. Click here to find out why I rate LFMD a Hold.- Published at
- by etfdailynews.com
positivepositiveReviewing Sigma Additive Solutions (NASDAQ:SASI) and Conversion Labs (OTCMKTS:CVLBD)
Read Reviewing Sigma Additive Solutions (NASDAQ:SASI) and Conversion Labs (OTCMKTS:CVLBD) at ETF Daily News- Published at
- by etfdailynews.com
positivepositiveConversion Labs (OTCMKTS:CVLBD) Trading Down 2.8%
Read Conversion Labs (OTCMKTS:CVLBD) Trading Down 2.8% at ETF Daily News- Published at
- by etfdailynews.com
positivepositiveReviewing Global Consumer Acquisition (NASDAQ:GACQ) and Conversion Labs (OTCMKTS:CVLBD)
Read Reviewing Global Consumer Acquisition (NASDAQ:GACQ) and Conversion Labs (OTCMKTS:CVLBD) at ETF Daily News- Published at
- by etfdailynews.com
positivepositiveTrans-Lux (OTCMKTS:TNLX) vs. Conversion Labs (OTCMKTS:CVLBD) Head to Head Contrast
Read Trans-Lux (OTCMKTS:TNLX) vs. Conversion Labs (OTCMKTS:CVLBD) Head to Head Contrast at ETF Daily News- Published at
- by globenewswire.com
mixedmixedSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in LifeMD, Inc. f/k/a Conversion Labs, Inc. of Class Action Lawsuit and Upcoming Deadline – LFMD
NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against LifeMD, Inc. f/k/a Conversion Labs,...- Published at
- by marketscreener.com
mixedmixedSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in LifeMD, Inc. f/k/a Conversion Labs, Inc. of Class Action Lawsuit and Upcoming Deadline - LFMD
NEW YORK, May 25, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against LifeMD, Inc. f/k/a Conversion Labs, Inc. and certain of its... | May 25, 2021- Published at
- by prnewswire.com
mixedmixedSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in LifeMD, Inc. f/k/a Conversion Labs, Inc. of Class Action Lawsuit and Upcoming Deadline - LFMD
/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against LifeMD, Inc. f/k/a Conversion Labs, Inc. ("LifeMD" or the "Company")...- Published at
- by thestreet.com
mixedmixedSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In LifeMD, Inc. F/k/a Conversion Labs, Inc. Of Class Action Lawsuit And Upcoming Deadline - LFMD
NEW YORK, May 18, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against LifeMD, Inc. f/k/a Conversion Labs, Inc.- Published at
- by benzinga.com
neutralneutralUnique Logistics International Reports Second Quarter Fiscal 2021 Earnings (Quarter ending November 30, 2020 and the six months ending November 30, 2020)
NEW YORK, Feb. 8, 2021 /PRNewswire/ -- Unique Logistics International, Inc. (formerly Innocap, Inc.) a global logistics and freight forwarding company, ...- Published at
- by rttnews.com
mixedmixedAGIO's ACTIVATE-T Hits Goals, EDSA Catches Eye, JNJ Provides Rosy Outlook, VXRT On Watch
Today's Daily Dose brings you news about the progress of Vaxart's oral tablet COVID-19 vaccine candidate; Vir Biotech's phase I trial of VIR-3434 in chronic hepatitis B virus; Sorrento's COVID-19 program; Agios Pharma's phase III trial of Mitapivat and Johnson & Johnson's rosy outlook for 2021.